Breakthrough in Multiple Myeloma Treatment: Starton’s STAR-LLD Shows Promise

Key points:

  • 100% of enrolled patients achieved partial response or better within 1-3 treatment cycles
  • No grade 3 or greater adverse events in neutropenia, thrombocytopenia, or diarrhea were reported
  • STAR-LLD showed milder and less frequent drug-related adverse events compared to Revlimid®

Starton Therapeutics has announced promising interim results from its Phase 1b clinical trial of STAR-LLD, a novel continuous delivery form of lenalidomide, for multiple myeloma treatment. The study demonstrates the potential for improved tolerability and efficacy compared to traditional oral lenalidomide (Revlimid®).

The trial, designed to assess safety, pharmacokinetics, and efficacy of STAR-LLD in combination with dexamethasone and bortezomib, met its primary objective of safety and tolerability. STAR-LLD is administered via continuous subcutaneous infusion, potentially addressing the intolerance issues associated with oral lenalidomide.

Dr. Jamie Oliver, Starton’s Chief Medical Officer, highlighted the significance of these results, noting that STAR-LLD’s lower toxicity at therapeutic doses could expand lenalidomide’s use in multiple myeloma treatment.

Pedro Lichtinger, Starton’s Chairman and CEO, emphasized the importance of addressing lenalidomide intolerance, which can adversely affect treatment efficacy and overall survival.

The company plans to prepare a data summary for the FDA while patients continue treatment for efficacy endpoints. Phase 2 studies in multiple myeloma and chronic lymphocytic leukemia are slated for 2025, marking a potential shift in blood cancer treatment paradigms.

Blood cancer.


Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BioMediaHub Logo